This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2013
  • /
  • 12
  • /
  • NICE recommends Aubagio for MS- Sanofi
Drug news

NICE recommends Aubagio for MS- Sanofi

Read time: 1 mins
Last updated: 7th Dec 2013
Published: 7th Dec 2013
Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) has now recommended the use of the oral Multiple Sclerosis drug Aubagio from Sanofi/Genzyme. Aubagio (teriflunomide) is recommended for treating adults with active relapsing-remitting MS. Sanofi has to provide the drug with the discount agreed in the patient access scheme. This is a change by NICE from the decision to not recommend teriflunomide made in the previous draft consultation document issued in September 2013.

Brain nerve cells
Brain nerve cells
Learning Zone

Multiple Sclerosis (MS) Learning Zone

Choosing the right treatment is critical to managing multiple sclerosis (MS). Consider your options with the latest data from over 40 MS clinical trial and congress resources.

Read more
How do you prefer to access medical updates and information?
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Blue test tubes arranged in a line, disappearing into the background
Drug news
Moderna reports H5 Flu data
Moderna’s H5 flu vaccine shows strong immune response in Phase 1/2; HHS ends late-stage funding, new paths explored.
Read more
Drug news
Cibotercept in PAH ends

Published: 30th May 2025

Read more
Drug news
Khindivi cleared for pediatrics

Published: 30th May 2025

Read more
See all news